Genprex (GNPX) Other Non-Current Assets (2016 - 2026)
Genprex (GNPX) posted quarterly Other Non-Current Assets of $1.5 million for Q1 2026, down 18.57% year-over-year from $1.8 million in Q1 2025, and down 16.59% quarter-over-quarter from $1.8 million in Q4 2025.
Genprex (GNPX) Other Non-Current Assets (2016 - 2026) Analysis & Trends
Genprex's Other Non-Current Assets history runs 11 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 18.57% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (down 18.57% YoY), while the FY2025 annual figure was $1.8 million, down 11.95% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $1.5 million, down from $1.8 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $3.6 million in Q3 2022, with the low at $10000.0 in Q1 2022.
- The 5-year median for Other Non-Current Assets is $1.8 million (2025), against an average of $1.4 million.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets slumped 99.52% in 2023, then surged 17613.4% in 2025.
- Genprex's Other Non-Current Assets stood at $21818.0 in 2022, then jumped by 14250.38% to $3.1 million in 2023, then plunged by 34.63% to $2.0 million in 2024, then slipped by 11.95% to $1.8 million in 2025, then dropped by 16.59% to $1.5 million in 2026.
- Business Quant data shows GNPX's Other Non-Current Assets at $1.5 million in Q1 2026, $1.8 million in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Genprex | 1.88 Mn | -13.28 Mn | - | 1.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.50 Mn |
| Dec 31, 2025 | 1.80 Mn |
| Sep 30, 2025 | 1.85 Mn |
| Jun 30, 2025 | 1.77 Mn |
| Mar 31, 2025 | 1.85 Mn |
| Dec 31, 2024 | 2.05 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | 10,000.00 |
| Mar 31, 2024 | 3.33 Mn |
| Dec 31, 2023 | 3.13 Mn |
| Sep 30, 2023 | 17,154.00 |
| Jun 30, 2023 | 17,154.00 |
| Mar 31, 2023 | 21,818.00 |
| Dec 31, 2022 | 21,818.00 |
| Sep 30, 2022 | 3.61 Mn |
| Jun 30, 2022 | 10,000.00 |
| Mar 31, 2022 | 10,000.00 |
| Dec 31, 2021 | 8,691.00 |
| Sep 30, 2021 | 638,101.00 |
| Jun 30, 2021 | 10,741.00 |